2000209-42-5

HTH-01-091 is a selective maternal embryonic leucine zipper kinase (MELK) inhibitor. HTH-01-091 provides a general framework for preclinical target validation.

HTH-01-091 is a potent and selective maternal embryonic leucine zipper kinase (MELK) inhibitor, with an IC50 of 10.5 nM. HTH-01-091 also inhibits PIM1/2/3, RIPK2, DYRK3, smMLCK and CLK2. HTH-01-091 can be uesd for breast cancer research[1].

DYRK4: 41.8 nM (IC₅₀); RIPK2; PIM1: 60.6 nM (IC₅₀); mTOR: 632 nM (IC₅₀); CDK7: 1230 nM (IC₅₀); PIM2; PIM3

[1] Huang HT, et al. MELK is not necessary for the proliferation of basal-like breast cancer cells. Elife. 2017 Sep 19;6:e26693. DOI:10.7554/eLife.26693